Cutaneous Squamous Cell Carcinoma (cSCC) Global Market Report 2025

The cutaneous squamous cell carcinoma (cSCC) market size has grown strongly in recent years. It will grow from $7.45 billion in 2024 to $7.9 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historic period can be attributed to the rising prevalence of non-melanoma skin cancers, an expanding elderly population, increased exposure to ultraviolet radiation, improvements in healthcare infrastructure, and the growing use of immunotherapy in oncology.

The cutaneous squamous cell carcinoma (cSCC) market size is expected to see strong growth in the next few years. It will grow to $9.9 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing availability of targeted therapies, heightened awareness of skin cancer prevention, the expansion of medical tourism for cancer treatments, the rising adoption of minimally invasive surgeries, and supportive government initiatives for cancer care. Major trends during this period include advancements in dermatology diagnostics, the development of advanced radiotherapy techniques, greater technological integration in dermatology, innovations in immunotherapy treatments, and progress in photodynamic therapy.

The increasing awareness of skin cancer is expected to drive the growth of the cutaneous squamous cell carcinoma (cSCC) market. Skin cancer, which results from the abnormal growth of skin cells, is often caused by excessive exposure to UV radiation and can range from benign to life-threatening. The rising awareness of skin cancer is attributed to expanded public health campaigns, improved access to information, and a stronger emphasis on early detection and prevention, leading to a higher demand for diagnostic and treatment solutions. Cutaneous squamous cell carcinoma (cSCC) plays a vital role in advancing skin cancer care by enabling targeted therapies, improving diagnostic accuracy, and enhancing patient outcomes, ultimately supporting better disease management. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization dedicated to eliminating cancer, reported 104,930 cases of skin cancer in 2023, marking a 3.2% increase from the 108,270 cases recorded in 2022. As a result, the growing awareness of skin cancer is expected to boost the expansion of the cutaneous squamous cell carcinoma (cSCC) market.

Leading companies in the cutaneous squamous cell carcinoma (cSCC) market are emphasizing advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted treatments, to improve patient outcomes and provide more effective solutions for managing advanced skin cancer. PD-L1, or programmed death-ligand 1, is a protein that binds to PD-1 receptors on T-cells, suppressing the immune response and enabling cancer cells to evade immune detection. In December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, received FDA approval for Unloxcyt (cosibelimab-ipdl), a novel treatment designed to block PD-L1, thereby enhancing the immune system’s ability to combat cancer. This therapy offers a safer and more effective treatment option, with its dual mechanisms of action providing a promising approach for managing advanced cutaneous squamous cell carcinoma (cSCC). The approval was based on findings from the CK-301-101 trial, which demonstrated clinically meaningful objective response rates and durable responses in patients with advanced cSCC.

In May 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Checkmate Pharmaceuticals for an undisclosed sum. This acquisition is intended to strengthen Regeneron’s focus on immuno-oncology by integrating vidutolimod, a promising clinical asset, alongside an innovative virus-like particle (VLP) delivery system. The addition of this technology enhances Regeneron’s portfolio of combination-ready strategies for treating difficult-to-manage cancers. Checkmate Pharmaceuticals Inc. is a US-based clinical-stage biotechnology company specializing in therapeutics for cutaneous squamous cell carcinoma.

Major players in the cutaneous squamous cell carcinoma (cSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.

North America was the largest region in the cutaneous squamous cell carcinoma (cSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cutaneous squamous cell carcinoma (cSCC) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Cutaneous Squamous Cell Carcinoma (cSCC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cutaneous squamous cell carcinoma (cSCC) is a form of skin cancer that originates in the squamous cells of the skin's outer layer. It most often develops in sun-exposed areas and can present as localized lesions or evolve into more aggressive forms that may metastasize to other parts of the body.

The primary treatment modalities for cSCC include both surgical and non-surgical approaches. Surgical treatments involve the removal of cancerous cells through techniques such as excision or Mohs surgery, aiming to completely eliminate the tumor while minimizing damage to surrounding healthy tissue. Diagnostic methods encompass computed tomography (CT), magnetic resonance imaging (MRI), and biopsy, which are employed across various settings such as hospitals, cancer institutes, ambulatory surgical centers, and more.

The cutaneous squamous cell carcinoma (cSCC) market research report is one of a series of new reports that provides cutaneous squamous cell carcinoma (cSCC) market statistics, including the cutaneous squamous cell carcinoma (cSCC) industry global market size, regional shares, competitors with the cutaneous squamous cell carcinoma (cSCC) market share, detailed cutaneous squamous cell carcinoma (cSCC) market segments, market trends, and opportunities, and any further data you may need to thrive in the cutaneous squamous cell carcinoma (cSCC) industry. This cutaneous squamous cell carcinoma (cSCC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cutaneous squamous cell carcinoma (cSCC) market consists of revenues earned by providing radiation therapy, chemotherapy services, immunotherapy and targeted therapy services, diagnostic services, and follow-up and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cutaneous squamous cell carcinoma (CsCC) market also includes sales of topical treatments such as 5-fluorouracil, imiquimod, monoclonal antibodies, and vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.